Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CTP-692 vs D-Serine in Healthy Volunteers
NCT03778320Phase 1Completed
- Sponsor
- Concert Pharmaceuticals
- Start
- Dec 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of deutarserine in schizophrenia (2 arms), sponsored by Concert Pharmaceuticals. Primary endpoints: Number of Adverse Events at 7 days and Plasma Exposure of CTP-692 at 48 hours. Started Dec 2018; status: completed.
02
Drugs
deutarserine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03778320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03778320.